Astellas Institute For

Apellis Pharmaceuticals, Inc., located in Waltham, MA, is dedicated to advancing innovation in complement science, aiming to transform treatment for patients suffering from a variety of debilitating diseases. With a commitment to embracing community voices, the company has achieved two product approvals in less than two years, underlining its focus on courageous and compassionate science. The company's pipeline reflects its mission to challenge conventional thinking and explore better solutions in healthcare. Apellis Pharmaceuticals is actively seeking experts to join their team as they work towards developing life-changing medicines across multiple rare disease research areas. Generated from the website

Ocular Therapeutix, located in Bedford, MA, is focused on transforming the treatment of retinal diseases, which significantly impact millions of Americans and often lead to blindness. Their ongoing clinical innovations, including the investigational therapy AXPAXLI (OTX-TKI), aim to reduce the treatment burden associated with retinal conditions like wet Age-Related Macular Degeneration. With a team that boasts extensive expertise and a strong track record in retinal disease management, Ocular Therapeutix aspires to improve long-term outcomes for patients by minimizing the need for frequent treatments. Their pipeline reflects a commitment to redefining patient care through advanced therapies and clinical trials. Generated from the website

Senesco Technologies is engaged in the research and development of genetic technologies to improve commercial agriculture and to treat major medical conditions in humans. Its platform technology is based on the identification and characterization of specific genes that are responsible for plant cell death and for programmed cell death in humans. The company is developing its technologies to address multiple opportunities within the global commercial agriculture industry, including extending the shelf life of perishable plant products, producing larger and leafier crops, increasing crop yields and reducing the harmful effects of environmental stresses, like drought. It is also researching applications of its technologies that may address the many human diseases associated with suppressed or premature apoptosis, including cancer, glaucoma and cardiovascular disease. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.